NCT02012569View on ClinicalTrials.gov

Determine the Haemostatic Efficacy of TT-173, Reducing the Bleeding Time in the Donor Site of Skin Grafting

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

BurnsTraumatic Lesions

Interventions

DRUG

TT-173

Bleeding of the lesion will be evaluated after each product application and will be recorded as bleeding vs. not bleeding. The product will be applied at 4 times for about 1 minute apart each application after skin graft obtention.

DRUG

Placebo

Trial Locations (1)

08860

Thrombotargets Europe, Castelldefels

All Listed Sponsors

lead

Thrombotargets Europe S.L

INDUSTRY

NCT02012569 - Determine the Haemostatic Efficacy of TT-173, Reducing the Bleeding Time in the Donor Site of Skin Grafting | Biotech Hunter | Biotech Hunter